Mycobacterium tuberculosis IgA ELISA Kit

Name: Mycobacterium tuberculosis IgA ELISA Kit
SKU: DEIA382
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum or plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Microtiter plate based Enzyme assay for the quantitative detection of human IgA antibodies to Mycobacterium tuberculosis in serum or plasma.

Contents of Kit

1 microtiter plate (96 wells) with 12 x 8 breakable strips suitable for 43 samples (duplicate measurements), including liquids: sample diluent, wash buffer, 4 standard solutions, conjugate solution, substrate solution and stop-solution.
1. Microtiter plate (96 wells), ready-to-use, coated with Mycobacterium tuberculosis antigens (12 x 8 individual breakable strips) sealed in an aluminum pouch with a desiccant bag.
2. Sample Diluent: 100 mL, ready-to-use, in PE-vial, PBS/BSA buffer, contains 0.05% 5-bromo-5-nitro-1.3-dioxane.
3. Wash Buffer, 10 x concentrate: 60 mL, in PE-vial, PBS buffer with Tween 20, contains 0.05% 5-bromo-5-nitro-1.3-dioxane.
4. Standard solutions: 2 mL each, readyto-use, in PE-vials, with different amounts of relevant specific antibodies against Mycobacterium tuberculosis, contains 0.05% 5-bromo-5-nitro-1.3-dioxane
5. Anti-human-IgA-conjugate solution: 12 mL, ready-to-use, in PE-vial, contains 0.05% 5-bromo-5-nitro-1.3-dioxane.
6. TMB substrate solution: 12 mL, ready-touse, in PE-vial (black), contains a solution of tetramethylbenzidine (TMB).
7. Stop-solution: 12 mL, ready-to-use, in PE-vial, 0.2 M H₂SO₄.
8. 1 instructions for use.
9. Plastic bag: Reseal-able, for the dry storage of unused microtiter plate/strips.

Storage

Store the test at 2 - 8°C. Unopened kit components are stable until the expiry date. The expiry date is printed on the labels of the aluminum pouch (microtiter plate), on the labels of the containers for the liquids and on the outer packaging. Do not use if the aluminum pouch is damaged. DO NOT FREEZE or expose temperatures above 30°C (except wash buffer, if crystal precipitate occurs).

Aluminum pouch with microtiter plate: Keep the test in unopened aluminum bag at 2 - 8°C.

Opened aluminum pouch with microtiter plate: Use up microtiter plate within 6 months!

Liquids: Keep liquid components at 2 - 8°C. Unopened liquids are stable until the expiry date. After first opening the liquids are stable for 6 months, if the bottles are tightly closed after every usage.

Precision

The intra-assay coefficient of variation (CV) of Human Tuberculosis Test kits was determined by ten-fold repeated measurements of several positive samples. The intra-assay CV is less than 10%.
Sensitivity and specificity for serum/plasma:
To determine the diagnostic sensitivity and specificity 985 serum and plasma samples from different regions were evaluated with the Mycobacterium tuberculosis IgA ELISA Kit. The results of the IgA ELISA were compared with clinical outcomes.
As gold standard for the diagnosis of "TB", a pathogen detection based on cultivation was defined (positive control group, a total number of 460 samples). As "negative control", samples of clinically healthy donors and patients with other diseases were measured (525 samples).
Extensive studies on samples of TB patients (culture positive) showed a sensitivity of 79.13% and a specificity of 96.95%. The cumulative sensitivity could be additionally increased by simultaneous measurement of IgG and IgA antibodies.
The positive predictive value (PPV) was 0.9579 with a negative predictive value (NPV) of 0.8413.

General Description

Human tuberculosis (TB) has become a global disease with its re-emergence in the Western countries in the last decades. According to WHO, more than 30 % of the world's population is estimated to be infected with the TB bacterium, Mycobacterium tuberculosis. TB is predominantly a disease of the respiratory tract, but can also affect other organs. People who are suffering from active pulmonary tuberculosis are highly infectious. TB kills yearly about 2 million people. Although, the TB bacterium was identified more than 100 years ago, the diagnostic methods, which are currently available, suffer from high price, poor sensitivity and specificity and are time consuming. The diagnosis of TB is usually made based on a combination of several laboratory tests.

The IgA ELISA is suitable for the quantitative detection of human IgA antibodies to Mycobacterium tuberculosis within 100 minutes. This test is an additional tool for rapid diagnosis of active tuberculosis (TB) using small amount of clinical sample.

General Notes

Infectious Disease ELISA Kits

Citations

Have you cited DEIA382 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Novel isoniazid derivative as promising antituberculosis agent

FUTURE MICROBIOLOGY

Authors: Volynets, Galyna P.; Tukalo, Michail A.; Bdzhola, Volodymyr G.; Derkach, Nataliia M.; Gumeniuk, Mykola I.; Tarnavskiy, Sergiy S.; Yarmoluk, Sergiy M.

Abstract

Background: A major focus of tuberculosis drug discovery is aimed at the development of novel antibiotics with activity against drug-resistant strains of Mycobacterium tuberculosis. Results: We have synthesized ten isoniazid derivatives and investigated for antibacterial activity toward M. tuberculosis H37Rv and isoniazid-resistant strain SRI 1369. It was revealed that only one compound, isonicotinic acid (1-methyl-1H-pyrrol-2-ylmethylene)-hydrazide (1), is active toward isoniazid-resistant strain with minimum inhibitory concentration value of 0.14 mu M. This compound is not cytotoxic toward human liver cells (HepG2; IC50 >100 mu M), demonstrates good permeability in Caco-2 cells. Accordingly to the results of plasma protein binding assay, unbound fraction of compound 1, which potentially exhibits pharmacologic effects, is 57.9%. Conclusion: Therefore, isonicotinic acid (1-methyl-1H-pyrrol-2-ylmethylene)-hydrazide is a promising compound for further preclinical studies.

Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

Authors: Kronenberger, Thales; Ferreira, Glaucio Monteiro; Ferreira de Souza, Alfredo Danilo; Santos, Soraya da Silva; Poso, Antti; Ribeiro, Joao Augusto; Tavares, Mauricio Temotheo; Pavan, Fernando Rogerio; Goulart Trossini, Gustavo Henrique; Bertacine Dias, Marcio Vinicius; Parise-Filho, Roberto

Abstract

The enzyme dihydrofolate reductase from M. tuberculosis (MtDHFR) has a high unexploited potential to be a target for new drugs against tuberculosis (TB), due to its importance for pathogen survival. Preliminary studies have obtained fragment-like molecules with low affinity to MtDHFR which can potentially become lead compounds. Taking this into account, the fragment MB872 was used as a prototype for analogue development by bioisosterism/retro-bioisosterism, which resulted in 20 new substituted 3-benzoic acid derivatives. Compounds were active against MtDHFR, with IC50, values ranging from 7 to 40 mu M, where compound 4e not only had the best inhibitory activity (IC50 = 7 mu M), but also was 71-fold more active than the original fragment MB872. The 4e inhibition kinetics indicated an uncompetitive mechanism, which was supported by molecular modeling which suggested that the compounds can access an independent backpocket from the substrate and competitive inhibitors. Thus, based on these results, substituted 3-benzoic acid derivatives have strong potential to be developed as novel MtDHFR inhibitors and also anti-TB agents.